Gapping down
In reaction to disappointing earnings/guidance:
- VRAY -51.2% (also CFO resigns effective September 30; so says it is in the midst of a retained search to find his replacement), FTCH -36.5% (also also agrees to acquire 100% of the shares of New Guards Group for a total enterprise value of $675 mln), NKTR -31.6%, PUMP -30.8% (also files to delay its 10-Q; co is in the process of conducting an internal review), FSLY -21.8%, WTRH -21.5%, DXC -21.2%, MESA -18.1%, QNST -16%, PYX -14.1%, RVLV -12.6%, AAXN -12.3%, CNDT -12.2%, VSLR -11.3%, HEAR -10.9%, TPC -9.5%, USCR -9.1%, AVT -8.9%, UBER -8.4%, AXDX -6.7%, XON -5.5%, ALTR -5.2%, DBX -5%, TSE -4%, TTD -3.8%, OSTK -3.2%, WPM -2.6%, TERP -2.6%, AL -2.2%, MAIN -1.9%, ATVI -1.8%, BHVN -1.8%, AIMT -1.5%, FLNT -1.4%, VRTU -1.4%, SYNA -1.3%
Other news:
- AMRN -20% (receives notice of FDA AdCom for Vascepa sNDA, anticipates that PDUFA date will be extended)
- CTST -9.8% (CannTrust's auditor is withdrawing its report dated March 27, 2019 on the Company's consolidated financial statements as at and for the year ended December 31, 2018)
- MAT -9.5% (discloses that, on August 6, it was made aware of an anonymous whistleblower letter)
- QSR -4.3% (files mixed securities shelf offering for an undisclosed amount; also files prospectus supplement for 20 mln common share offering by selling shareholder - affiliate of 3G Capital Partners)
- PMT -4.1% (prices underwritten public offering of 8 mln common shares of beneficial interest for total estimated gross proceeds of approximately $174 mln)
- KALA -3.3% (receives complete response letter from FDA for KPI-121 0.25% NDA; clinical trial will be needed to support a resubmission)
- STML -3% (prices underwritten public offering of 5 mln shares of its common stock at a price of $15.25 per share)
- SILK -1.1% (prices upsized secondary public offering of 4.2 mln shares of common stock by certain selling stockholders at $39.50 per share)
Analyst comments:
- N/A.